Skip to main content
Premium Trial:

Request an Annual Quote

Ted Snelgrove

Liquid biopsy firm Lexent Bio has appointed Ted Snelgrove as its chief business officer. In the roll, Snelgrove will work closely with the CEO and  the company's board on test launch strategy, commercial team development, and corporate partnering.

Snelgrove's experience in molecular diagnostics includes building and leading the original commercial team for Genomic Health's Oncotype DX product line. He also built the commercial team at Crescendo Bioscience, now part of Myriad Genetics, promoting the firm's Vectra DA for disease management in rheumatology. He was CEO at CellScape, an early player in the NIPT market, served as the oncology/hematology business unit head at Jazz Pharmaceuticals, and held C-Level roles at Counsyl and more recently at Guardant Health.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.